Clean Cells to build new production facility

Article by Amanda Doyle

BIOPHARMACEUTICAL company Clean Cells has invested €13m (US$15.3m) in a new production facility in France that would quadruple its analysis and production capacity.

Clean Cells, part of the Clean Biologics group, aims to play a role in speeding up the development and time-to-market for innovative treatments and Covid-19 vaccines. It claims that the new facility will be Europe’s largest quality control and cell bank production facility. It will increase biopharmaceutical quality control capacity and decrease time-to-market for products in Europe. Clean Cells will be able to increase its production capacity of cell banks for vaccines, therapeutic antibodies, and gene therapies. Construction began in July and is expected to be completed in September 2022.

Olivier Boisteau, Co-founder and Strategic Adviser at Clean Biologics, said: “The production of cell banks for vaccines and therapeutic antibodies has known a strong upward trend over the past two years. We’ve hit the maximum capacity in our laboratories to offer our clients the most optimal services, which is exactly why we are almost doubling the number of production suites.”

Joseph Jammal, CEO of Clean Biologics, said: “For over 20 years, Clean Cells has been serving the biopharmaceuticals development market. Its expertise and know-how is growing stronger every day, in particular since the outbreak of Covid-19 and the race to develop a vaccine. This new and state-of-the-art site enables our teams to work in the best possible conditions to continue their analysis and production work.”

Article by Amanda Doyle

Staff Reporter, The Chemical Engineer

Recent Editions

Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.